Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients

30 Sept 2016

Abstract excerpt

Molecular biomarkers may facilitate the distinction between aggressive and clinically insignificant prostate cancer (PCa), thereby potentially aiding individualized treatment. We analyzed cysteine dioxygenase 1 (CDO1) promoter methylation and mRNA expression in order to evaluate its potential as prognostic biomarker. CDO1 methylation and mRNA expression were determined in cell lines and formalin-fixed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research
Share to Urological Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27689475
DOI: 10.1080/15592294.2016.1241931

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patientsPMID 27689475Read ↗

Promoter Methylation of <i>CDO1</i> Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival OutcomeSemantic proximity Read ↗

Promoter Hypermethylation and Androgen Receptor Regulation Unveil Dual Oxidase 1 as a Tumor Suppressor in Prostate AdenocarcinomaSemantic proximity Read ↗

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer PatientsSemantic proximity Read ↗

ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancerSemantic proximity Read ↗

Epigenetic silencing of MEIS2 in prostate cancer recurrenceSemantic proximity Read ↗

Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomesSemantic proximity Read ↗

Identification of New Differentially Methylated Genes That Have Potential Functional Consequences in Prostate CancerSemantic proximity Read ↗

Targeted demethylation of the CDO1 promoter based on CRISPR system inhibits the malignant potential of breast cancer cellsSemantic proximity Read ↗

DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrenceSemantic proximity Read ↗

Development and Clinical Validation of a Real-Time PCR Assay for PITX2 DNA Methylation to Predict Prostate-Specific Antigen Recurrence in Prostate Cancer Patients Following Radical ProstatectomySemantic proximity Read ↗

Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancerSemantic proximity Read ↗

Prognostic and immune correlation of IDO1 promoter methylation in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.